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Setting the stage
When evolution chose apatite to make the rigid part of bone,
instead of carbonates which most invertebrates use [1], it set
the levels of calcium and phosphate that interstitial fluid of bone
must have to keep the apatite from dissolving and permit the
bone to form new crystals in the course of its remodelling or
repair. As well, stability of apatite requires pH be kept near 7.0,
for lower values favor brushite [1]. At blood pH of 7.4, blood
concentrations of calcium and phosphate ions, 1.15 m and 1.1
to 1.5 m, respectively, create an ion product (1.26 to 1.72
mM2) higher than the solubility product of bone mineral, 0.83
mM2. The choice of kidneys that begin their work by massive
ultrafiltering of blood, and end it by conserving almost all the
filtered water, set the stage for stone disease and nephrocalci-
nosis, by obliging kidneys to deliver calcium and phosphate
ions into tubules at a rate determined by filtration and the rigid
needs of apatite stability. Additional selections, of transporters
for both ions, and the sites of reabsorption, made the risks of
stones and nephrocalcinosis even higher, and created needs for
natural defenses to retard the nucleation and the growth of
calcium crystals.
Urine mineral levels and supersaturations
We have pointed out elsewhere [2] that conservation alone
relates final urine
D(a—/3) f[i]=—
g (l—r)
excretions of minerals to their plasma ionic concentrations ([ii),
glomerular filtration rate (g), and fractional reabsorptions (r), so
that in steady states, when excretion equals the difference
between net absorption from diet, or total dietary mineral
content (D) times fractional intestinal absorption () and the
fraction of diet mineral retained in the body, mainly in bone (/3),
and given a fixed ratio of ultrafilterable to ionic level (t) all terms
can be given in one equation of state.
Given the need for blood ion levels determined by the
character of bone apatite, urine levels of calcium and phosphate
depend upon the balance between g and r, so that lower r
requires greater excretions. For man, values of g range from 130
to 200 liters daily, and r for phosphate from 70 to 90%, for
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calcium 92 to 98%; one can make a nomogram relating g to r for
the lower and upper boundaries of normal phosphate and
calcium excretion rates (Fig. 1). The graph makes clear that
higher fractional reabsorption for phosphate could have permit-
ted a urine excretion like that of calcium, and eliminated
calcium phosphate supersaturation, and higher calcium frac-
tional reabsorption, similar to that of sodium, could have
lowered urine calcium to below 20 mg daily, avoiding any
calcium salt supersaturation. Instead, evolution settled on
lower reabsorption efficiencies, creating driving forces for cal-
cium phosphate and other calcium salt crystallizations (Table
1). We show brushite supersaturation, not apatite, as brushite
will form at pH 6, and then hydrolyse to apatite, slowly, so
brushite supersaturation will tend to govern crystallization.
Nucleation and promoters
Everyone who studies stone disease views urine supersatu-
ration as tinder, an unstable source of free energy needing for
its release only some small and local perturbation, which
comes, we think, mostly in the form of surfaces on which
solution ions find ready lodgement, usually because of charged
attachment sites, and, having lodged, begin to form nuclei of a
crystal. Uric acid or sodium hydrogen urate crystals seem likely
nucleation promoters [3], though cell surfaces and even cell
debris, and aggregated proteins, such as Tamm Horsfall protein
could also serve. Urine has sufficient supersaturations to create
sodium hydrogen urate or uric acid crystals (Table 1).
Apatite and brushite crystals also could serve as nuclei for
calcium oxalate, which makes up the mass of most stones [4],
and may well do so given that almost all stones [4] contain some
apatites. Conventional reasoning never has provided any spe-
cial origin for apatite crystals in kidney tubules, presuming that
apatite precursors like brushite could form in collecting ducts,
as water extraction proceeds, just as calcium oxalate nuclei
form, and the two species could interact toward the end of the
nephron.
Supersaturations within the nephron
We think otherwise, lately, and have proposed that condi-
tions in the thin segments of the loop of Henle might create
special and extreme supersaturations that favor brushite and
even calcium carbonate nucleation [5]. The idea arose in 1986,
during a perusal of micropuncture data concerning renal min-
eral transports, and led to a seminar about possible thin
segment supersaturation. As the thin descending segment loses
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Fig. 1. Relationship between fractional reabsorption, glomerular fil-
tration rate, and urinary excretion for calcum and phosphorus neces-
sary to maintain the blood ionized calcium at 1.15 mm/liter and the
blood phosphorus level at 1 mm/liter. As glomerular filtration rates (g)
fall, fractional reabsorption (y axis) must fall in a curvilinear and
accelerating manner at any given value of urine excretion, in order to
maintain constant blood values. The shaded zone spans the region
between the lower and upper limits of the normal range for calcium or
phosphorus loss in the urine. Used with permission from "Calcium,
Phosphorus and Magnesium" a chapter in Renal Physiology in Health
and Disease, edited by B BRENNER, FL COE, FC RECTOR, Philadel-
phia, WB Saunders, 1987.
water to a hypertonic medullary interstitium, calcium concen-
tration reaches about 3 m by the bend of the limb in rodents
[61, and pH and PCO2 match those of blood [7].
At the seminar and at the 1989 meeting of the American
Society of Nephrology [51, we presented calculated supersatu-
rations for calcite and brushite at the bend of the ioop, and
showed they exceeded those of blood, any other nephron
segment, and probably the upper limits of metastability. As
well, we presented evidence that solutions like those of the thin
segment produce an apatite type of solid phase, in vitro.
Naturally, one wishes to show, here, the evidence for crystal-
lization potentials in thin segment, but the data still await their
primary publication, so I can only summarize our abstract [5]
and meeting presentation.
Anyone can consult the micropuncture literature and confirm
the obvious alkaline, high calcium environment of the thin
segment at its bend in rodents, and corresponding potential for
calcium phosphate and carbonate formation, and consider the
possible role of alkaline earth crystals in stone disease. Nuclei
formed in thin segment move down stream, and their fate to act
as nuclei, to grow into stones, or to dissolve, must depend upon
the balance between water extraction and pH lowering by distal
nephron proton transport, calcium reabsorption in thick as-
cending limbs and late nephron segments, and phosphorus
concentration.
Phosphorus concentration in the thin segment and later
nephron segments depends upon its filtered load and fractional
reabsorption, which themselves depend upon the parathyroid
Table 1. Summary of urine supersaturations in normal men and
women
Urine chemistry
Normal
men
Normal
women
pH 6.04 0.05 6.09 0.05
Volume liter/24 hr 1.28 0.04 1.30 0.06
SUPERSATURATIONS
Calcium oxalate 6.63 0.40 4.03 0.28
Brushite 3.22 0.23 1.67 0.22
Hydrogen urate 2.68 0.26 2.09 0.28
Sodium hydrogen urate 8.44 0.57 4.74 0.54
a>
C.)
a)C
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Fig. 2. Urine citrate versus calcium concentration (± SEM) in women
(open symbols) and men (closed symbols) with (square) and without
(circles) calcium oxalate nephrolithiasis. Used with permission from
reference 15 (Kidney mt 30:85—90, 1986).
hormone (PTH)—vitamin D axis. High phosphorus intakes will
increase filtered load and PTH [8], raising phosphorus delivery
into thin segments. Low phosphorus diets will do otherwise, so
diet phosphorus may be critical to stone disease and nephro-
calcinosis, though presently unappreciated as even a risk fac-
tor. Incidently, students of chronic renal failure progression
have long viewed diet phosphorus loading as a leading culprit
[9], which thin segment supersaturation predicts, and which
was alluded to in a recent review [10] by someone present at the
1986 seminar.
The character of the defenses
At first glance, the normal supersaturations of urine, which
must begin in the collecting ducts as water is extracted, and the
apparent supersaturations in the thin limbs with respect to
brushite and calcium carbonate, as well, seem ominous, and
lead one to expect universal intra-nephron and urinary crystal-
lizations. Normal urine often does contain crystals [11], mainly
calcium oxalate, and urines with highest measured values of
supersaturation most frequently contain crystals. But calcific
stones and nephrocalcinosis, or even calcium salt crystalluria
gross enough to be perceived as gravel or to cause hematuria
occur only occasionally, in perhaps less than 1% of people, and
when these occur it is in people whose urine calcium oxalate
supersaturations exceed those of most normal people because
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Fig. 3. Effects of inhibitors on COM crystal
aggregation. Inhibition of COM crystal
aggregation (y-axis, left) by THP (U), normal
urine NC (0), albumin (s), f3-2 microglobulin(•), stone former urine NC (S), NC from
stones (A), and CIT (•) increased with their
concentrations (x-axis). All values are means
SE. 1 Differs from control, P < 0.05; * <
0.01; < 0.001. CIT is also without effect
at I x iO M (not shown). Particle diameters
(y-axis, right) are calculated. Used with
permission from reference 16 (Am J Physiol
257:F99—F106, 1989).
of genetic hypercalciuria [12], hyperparathyroidism [13], or
other conditions of hypercalciuria, or because of high urine
oxalate levels [14], or those who may be prone to crystallize
uric acid salts because of hyperuricosuria, and have stones
because of increased nucleation [3]. Put another way, clinical
crystalluria, stone disease and nephrocalcinosis seem surprising
for their low frequency.
Citrate as defense
Citrate stands out as well defined, and a clear protection. In
urine at m concentrations, citrate forms a soluble salt with
calcium, so less can combine with organic acids like oxalate and
phosphate, to create stones. Normal women seem superior to
men in having a very high ratio of urine citrate to calcium (Fig.
2), and normal men resemble women who form stones, perhaps
why four of every five stone formers is male. Men with stones
have low citrate levels even compared to the relatively low
values among normal men. Why normal women have higher
citrate than men, and why women with stones excrete less
citrate must involve differences in renal tubule citrate reabsorp-
tion, as men and women, and stone formers all have the same
plasma citrate levels [151.
Tamm Horsfa!1 protein (THP)
Because it inhibits the self aggregation of calcium oxalate
monohydrate (COM) crystals (Fig. 3), THP reduces the forma-
tion of large masses out of small microcrystallites, a process
______________
_______
that could convert harmless crystalluria into a coarse sludge or
create intranephronal masses large enough to occlude collecting
ducts and serve as anchored crystallization sites [16]. Other
urine proteins inhibit aggregation, too, but none within their
usual urine concentration range except for Nephrocalcin (NC),
a newly described protein detailed below. THP cannot reduce
rate of COM crystal growth, nor COM nucleation rate [17].
Citrate does not inhibit COM aggregation, and might promote
aggregation at high concentrations (Fig. 3).
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Fig. 4. Surface charge (Zeta potential) of COM crystals. Zeta potential
(y-axis) of crystals incubated with THP (LU, normal urine NC (0), stone
former urine NC (•), and stone NC (A) became negative vs. control
(crosshatched region, above broken y-axis). Above l0 M, increasing
concentration did not increase negativity of potential. Used with
permission from reference 16 (Am J Physiol 257:F99—F106, 1989).
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Fig. 5. A. Adsorption of nephrocalcin (NC) to calcium oxalate crystals measured using serum from single rabbit (tNI) (ordinate) vs. NC
concentration (abcissa) in incubation medium. Crystals of calcium oxalate monohydrate were incubated with NC for 2 hr, then probed using tN I.
After washing, tNl was probed using peroxidase labeled goat anti-rabbit immunoglobulin (lgG). Values SE do not depart from the linear
relationship predictd by simple mass action for double reciprocol plot. Slope of regression is 2.32 0.053, intercept is 1.85; dissociation constant,
calculated from ratio of slope to intercept is 1.24 0.028 x l0- M. The regression was significant, F = 1865, P < 0.001. B. Reduction of growth
of same crystals by NC (insert) followed by Langmuir-type isotherm with dissociation constant of 1.53 0.3 x lO M. Regression was significant,F = 24, P < 0.05. C. Relationship between reduction of crystal growth (ordinate) and adsorption of NC (abcissa) to calcium oxalate crystals.
Incubations and measurements as in A and B. Fall in growth rate constant (k3) compared to growth rate (k2) did not depart from linear dependence
on protein absorption. Used with permission from reference 18 (Am J Physiol 255:Fl l97—F1205, 1988).
Fig, 6. Immunoperoxidase staining of cultured tubule cells. Immunoperoxidase reaction stains cells incubated with EWI (A and C), but not cells
incubated with nonimmune serum (B and U). Dark cytoplasmic pigment is in all cells. Original magnification x400. Used with permission from
reference 19 (Am J Physiol 257:F390-F398, 1989).
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Fig. 7. Force area curves for A-D inhibitors
(Figs. 7A-#, respectively), from normals (•) and
patients (0). Surface films of 135 g protein were
compressed and expanded between 600 and 20
cm2 at 2.2 cm2lsec. Collapse pressures (dyne per
centimeter) of normal A-C exceeded
corresponding values for patient materials: 33.2
vs. 27.8, 41.4 vs. 27.6 and 36 vs. 20.4; values for
300 D were nearly the same: 34.2 vs. 32. Used withpermission from reference 22 (J Clin In vest 76:
1455—1462, 1985).
showing that inhibition must depend upon adsorption to crys-
tals.
In the collecting ducts and final urine, THP and NC could act
as parallel inhibitors, both inhibiting aggregation, and NC
inhibiting the growth of small microcrystallites, and nucleation
of new microcrystallites off the surfaces of crystallites already
present. Their net effects would keep small nuclei small and
separate, so they could be eliminated as harmless microscopic
crystalluria. Given the universal supersaturation of urine, and
presumably papillary collecting duct fluid, the proteins may be
an important reason why kidneys can eliminate calcium at mM
concentrations and be relatively immune to stone formation.
Primary cultures of mouse proximal tubule cells produce NC
[191 as judged by chemical purification of NC from conditioned
medium and immunohistochemical staining of cultured cells
(Fig. 6). The cells stained uniformly, and these same cultures
could produce 1,25(OH)2D3 from 25(OH)D substrate, showing
they retained at least one important differentiation marker.
The site of staining in human kidney tissue originally was
thick ascending limb [20] using an antibody that did not recog-
nize THP, a confusing finding given our culture results. With
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THP can influence crystal aggregation only after it enters the
tubule fluid, in the thick ascending limb of Henle's loop, so even
if it could inhibit brushite or calcite aggregation, such activity
could not be useful within the kidney. The mechanism of THP
inhibition involves adsorption to crystals, because COM crys-
tals incubated with THP reverse their surface potential, as
shown (Fig. 4) by altered electrophoretic mobility, and using
antibody techniques we [18] could show THP adsorption to
COM crystals even though such coated crystals grew at the
same rates as uncoated crystals.
Nephrocalcin (NC)
NC inhibits the growth, aggregation, and nucleation of COM
crystals. Growth inhibition proceeds in parallel with crystal
adsorption of NC (Fig. 5), as one would expect, the adsorption
and inhibition affinity constants both approximating 0.5 .tM
[181. Aggregation inhibition (Fig. 3) by NC is half maximal at
0,05 /LM, about tenfold below the concentration needed for
inhibition of growth. Inhibition of nucleation [17] occurs when
NC is in the solution bathing COM crystals, or when crystals
are coated, and then transferred to an incubation medium,
0 100 200 300 0 100 200
A, cm2 A, cm2
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Fig. 8. Lan gmuir adsorption coefficients. Values SEM for normals(N-crosshatch) and patients (P, open bars) for the A-D fractions.
Ordinate shows the slopes of langmuir type isotherm regressions.
Patients and normals differed, P < 0.01 for A and B, and P < 0.001 for
C and D. (Note changed scale indicated by broken ordinate line.) Used
with permission from reference 22 (J Clin Invest 76: 1455—1462, 1985).
another antibody, we [211 showed proximal tubule and thick
ascending limb staining, and the latter could not be due to THP
cross reactivity which our antibody did not possess. Presum-
ably, NC can be produced in both segments, but in slightly
different forms, and antibodies vary in their ability to detect the
two.
Given the apparent dual locale of NC production, NC could
prevent nucleation, growth, and aggregation in the 1oop of
Henle, as well as in collecting duct. Missing are data concerning
effects of NC on aggregation, growth, and nucleation of
brushite and calcite, the phases relevant to the thin segment.
Stone disease and impaired defense
Reduced citrate, especially in women who form stones, raises
urine calcium ion levels, and certainly could promote stones by
raising supersaturations. The association of reduced urine cit-
rate with stone forming supports the importance of citrate in
normal defense against crystallization. Needed is a definitive
trial of citrate as monotherapy versus placebo control.
Abnormal forms of NC seem to occur in urine of patients with
calcium stones [22], the abnormality including an absence of
gamma carboxyglutamic acid (gla), normally present in NC,
very reduced air-water interfacial film stability (Fig. 7) and
reduced inhibition by about 1/2 of the NC present in urine,
namely the two fractions eluting at relatively high ionic strength
from ion exchange columns (Fig. 8). The loss of gla could alter
molecular conformation, reducing amphicility that confers sta-
ble interfacial film forming properties and derives from spatial
separation of hydrophobic and hydrophillic regions along the
molecule. Such amphiphilicity could be crucial for an inhibitor,
because hydrophilic regions would preferentially adsorb to the
charged crystal surface, leaving hydrophobic regions to face the
solution, and offer few charge association sites for solution ions
to attach to and set up new nucleations. NC from stone formers
also inhibits COM aggregation less than normal NC (Fig. 3), so
stone formers may be deficient in two separate defenses.
Thus far, THP abnormalities have not been described in
stone formers, though they would be very important in that the
THP amino acid sequence and genomic DNA gene sequences
both have been determined [23]. We have identified six stone
formers, who each formed many stones, and four of these
produce THP that inhibits COM aggregation weakly. One of
these has family members seemingly affected in a similar
manner. These observations await primary publication, and
cannot be shown here.
An overview of the compromise
Evolution had choices concerning the calcium crystallization
problem, and seemingly choose one coherent strategy out of
several available. Using apatite for bone stiffening coupled with
a kidney dependent upon high filtration rate set the main
character of the problem, as large amount of calcium must enter
such a kidney and will travel downstream to water reabsorption
sites unless high efficiency transporters remove almost all of it.
The compromise includes a high reabsorption fraction for
calcium, but still not high enough to avoid risk of crystalliza-
tion; this latter would have required 99.5% or higher fractional
reabsorption, in the range of values for sodium.
Crystallization of calcium oxalate seems foreordained given
the choice of the lower calcium reabsorption efficiency, since
oxalate production is ubiquitous in animals because all lack an
oxalate oxidase. Higher phosphate reabsorption fractions for
phosphorus would have reduced risks of brushite crystalliza-
tions in the thin segment, but we cannot be certain, as yet, what
biological consequences brushite crystallization possesses. In-
hibitors certainly evolved to offset supersaturations, and must
seem less costly in an evolutionary sense than the achievement
of higher fractional calcium reabsorption.
As well, materials like citrate, that form soluble calcium salts,
play a protective role. In particular, urine citrate increases
during alkali loading [24], when urine and collecting duct fluid
pH would be high, so calcium phosphate and carbonate crys-
tallizations are particularly defended against. Conditions like
pregnancy, characterized by hypercalciuria, alkaline urine, and
little or no augmentation of urine citrate stand out as particu-
larly important to understand, as stone disease and crystalluria
do not occur during pregnancy yet should be a serious problem.
70
65
60
20
15
10
70
65
60
20
N P N P N P N P
Coe and Parks: Crystallization inhibitors 631
Protein inhibitors during pregnancy, by deduction, should
therefore be of especial interest.
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